At the conclusion of this activity, participants will be able to:

  1. Understand the fraction of patients with ovarian carcinoma who will have cancers with BRCA1 or BRCA2 mutations
  2. Define the standard of care for treatment of advanced ovarian cancer with BRCA mutations
  3. Define different predictors of response to PARP inhibition in ovarian cancers
Session date: 
06/03/2022 - 8:00am to 9:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Elizabeth Swisher, MD